Bender Robert & Associates increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.2% during the second quarter, Holdings Channel reports. The fund owned 56,425 shares of the life sciences company’s stock after buying an additional 112 shares during the period. Illumina makes up approximately 6.0% of Bender Robert & Associates’ holdings, making the stock its 4th largest position. Bender Robert & Associates’ holdings in Illumina were worth $9,791,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ILMN. Bank of Montreal Can raised its stake in Illumina by 61.0% in the first quarter. Bank of Montreal Can now owns 113,182 shares of the life sciences company’s stock worth $19,314,000 after buying an additional 42,876 shares during the last quarter. Eastern Bank bought a new stake in Illumina during the first quarter worth about $256,000. Fox Run Management L.L.C. bought a new stake in Illumina during the first quarter worth about $939,000. DnB Asset Management AS raised its stake in Illumina by 18.3% in the first quarter. DnB Asset Management AS now owns 16,089 shares of the life sciences company’s stock worth $2,745,000 after buying an additional 2,490 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in Illumina by 41.0% in the first quarter. Nisa Investment Advisors LLC now owns 6,190 shares of the life sciences company’s stock worth $1,056,000 after buying an additional 1,800 shares during the last quarter. 93.91% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Illumina, Inc. (NASDAQ ILMN) opened at 194.25 on Monday. The firm has a market capitalization of $28.36 billion, a P/E ratio of 38.97 and a beta of 0.83. Illumina, Inc. has a one year low of $119.37 and a one year high of $199.95. The company has a 50-day moving average price of $179.63 and a 200 day moving average price of $173.73.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.68 by $0.14. The firm had revenue of $662 million for the quarter, compared to the consensus estimate of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.86 EPS. Analysts expect that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/14/illumina-inc-nasdaqilmn-is-bender-robert-associates-4th-largest-position.html.

Several research analysts have weighed in on ILMN shares. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 price target for the company in a report on Monday, April 17th. Cantor Fitzgerald boosted their price target on Illumina from $155.00 to $170.00 and gave the company a “neutral” rating in a report on Wednesday, April 26th. Cowen and Company reiterated an “outperform” rating and issued a $200.00 price target on shares of Illumina in a report on Wednesday, April 26th. Deutsche Bank AG reiterated a “hold” rating and issued a $175.00 price target (up from $165.00) on shares of Illumina in a report on Saturday, April 29th. Finally, Morgan Stanley reiterated an “underweight” rating and issued a $115.00 price target (up from $108.00) on shares of Illumina in a report on Monday, May 15th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $177.01.

In related news, Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total value of $2,561,550.00. Following the transaction, the director now owns 534,176 shares in the company, valued at approximately $91,221,235.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marc Stapley sold 2,000 shares of Illumina stock in a transaction on Monday, June 12th. The stock was sold at an average price of $170.85, for a total transaction of $341,700.00. Following the completion of the transaction, the executive vice president now owns 41,341 shares in the company, valued at approximately $7,063,109.85. The disclosure for this sale can be found here. Insiders sold a total of 134,010 shares of company stock worth $23,946,015 in the last quarter. Insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.